CHK1 inhibition as a strategy for targeting Fanconi Anemia (FA) DNA repair pathway deficient tumors - Wikidata - wikimedia - TriplyDB

CHK1 inhibition as a strategy for targeting Fanconi Anemia (FA) DNA repair pathway deficient tumors

CHK1 inhibition as a strategy for targeting Fanconi Anemia (FA) DNA repair pathway deficient tumors

http://www.wikidata.org/entity/Q37168650

about

Chk1 suppressed cell death Susceptibility pathways in Fanconi's anemia and breast cancer Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapy Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer Exploiting the Fanconi Anemia Pathway for Targeted Anti-Cancer Therapy Targeting DNA damage response in cancer therapy Mechanisms of a novel anticancer therapeutic strategy involving atmospheric pressure plasma-mediated apoptosis and DNA strand break formation.Targeting EGFR induced oxidative stress by PARP1 inhibition in glioblastoma therapy Chk1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers.New insights into checkpoint kinase 1 in the DNA damage response signaling network.Non-specific chemical inhibition of the Fanconi anemia pathway sensitizes cancer cells to cisplatin.Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo.Spontaneous abrogation of the G₂DNA damage checkpoint has clinical benefits but promotes leukemogenesis in Fanconi anemia patients.RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma Dynamics of DNA damage induced pathways to cancer Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites.mTORC1 and DNA-PKcs as novel molecular determinants of sensitivity to Chk1 inhibition Orthogonal targeting of EGFRvIII expressing glioblastomas through simultaneous EGFR and PLK1 inhibition.Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF-κB and Bim Bone marrow failure in Fanconi anemia is triggered by an exacerbated p53/p21 DNA damage response that impairs hematopoietic stem and progenitor cells.Homologous recombination and its regulation Inhibition of Chk1 with the small molecule inhibitor V158411 induces DNA damage and cell death in an unperturbed S-phase.FANCA safeguards interphase and mitosis during hematopoiesis in vivo.Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736 Chemogenetic profiling identifies RAD17 as synthetically lethal with checkpoint kinase inhibition.The ATM signaling network in development and disease.Werner syndrome helicase has a critical role in DNA damage responses in the absence of a functional fanconi anemia pathway.DNA damage tolerance: a double-edged sword guarding the genome Targeting an Achilles' heel of cancer with a WRN helicase inhibitor Targeting the LKB1 tumor suppressor.The carboxyl terminus of FANCE recruits FANCD2 to the Fanconi Anemia (FA) E3 ligase complex to promote the FA DNA repair pathway.Fanconi anaemia: from a monogenic disease to sporadic cancer.The potential of exploiting DNA-repair defects for optimizing lung cancer treatment.Current clinical management of Fanconi anemia.DNA interstrand cross-link repair: understanding role of Fanconi anemia pathway and therapeutic implications.DNA replication stress and cancer: cause or cure?Biochemical and cell biological assays to identify and characterize DNA helicase inhibitors.Targeting the ATR-CHK1 Axis in Cancer Therapy A Network of Conserved Synthetic Lethal Interactions for Exploration of Precision Cancer Therapy.Novel targets for ATM-deficient malignancies.

P2860

Q21203552-8BC192AE-6C13-4E40-8759-80D859F3B675 Q24628760-F72DA6FC-9DE6-469D-B957-FC24DB77BE24 Q26745686-B401C365-BA9E-4B89-9FE6-16308197E67F Q26783551-87CBD047-0F81-47F5-9546-5199CF445765 Q26801593-8AE7AD26-1EF6-4E89-9B87-15181835D82D Q27023204-8D0EAFFC-CC1C-40B4-B782-351AA43C6330 Q33465772-E7BFBFA0-9BC3-4A69-9147-BEC52D838931 Q33598694-6A6A223A-B970-428F-8224-20FB954E7BEA Q34062570-4C40095A-BE5C-4762-A7C0-7BFDE21B8F3C Q34129155-C86ADB0B-525B-4F05-9B8F-B8E14E7538EE Q34248336-FE9A0ED4-15B9-4566-B04A-64CEF5888B0F Q34309214-5E42F371-0C82-478B-865A-E0464C9133BA Q34428974-34B33C7E-A115-4C20-BD56-AE2AB271C26F Q34602599-020D19C4-63C9-4BA1-8C24-8AE5E9CAD679 Q34983908-91467956-F3C4-4295-9468-DAB93B9222FC Q35751401-38FD2C9E-F6F0-4674-A028-13C69954921A Q35809470-42D55536-7A9A-4882-B309-25249B83A9CC Q35828426-71EC97D6-8689-4E1C-97DC-A12B92B19751 Q35982670-EF1F48B7-582B-405B-A9F5-CF4FD7093ED7 Q36083918-64ACA507-0579-4C3D-8EB2-4E3DFDC7EFC4 Q36106937-3AAFC6E2-4CA6-46A5-9017-2F4459E4C13C Q36187661-E861A2C4-2D23-4AA5-A3C8-228D8AFD68F3 Q36338599-9FA1C262-EE1C-494F-A22E-65B345413269 Q36545701-F66E5481-B19A-408E-B0B5-AE37AC872269 Q36546455-7EECA962-F5C7-47C0-8878-F7EE74AE2014 Q36712849-085FE14D-019F-4446-AD6A-C4BD64E62C20 Q37154365-2DC32FA3-E09E-4BF9-B0AF-56F8D9D6CBA9 Q37187991-E1BA37B3-F384-4F75-8E47-80FD58F06484 Q37452985-3D976F67-AA5E-4EDF-9E30-D95D68BCF2E3 Q37506032-001C49EF-BF6B-4B3C-90F4-CEE60BEAF3D5 Q37622640-D894D9AF-6B9A-4AB9-A756-7BB9C6E9BF73 Q37865169-87AFE15C-50B7-4B86-9D98-B1F7FFB8E76A Q37983690-E22F2ED1-6733-44E2-B79F-57E12AC1F776 Q38059251-0F473E43-CB2C-480B-BBBF-1FDDEFDA3083 Q38121955-14142D47-12B3-44B9-9E1E-FBE40F5050AE Q38652528-1A0A0F70-0B4E-407B-B753-8FE6BCC4AF8A Q38804207-54EA6560-8259-4D55-8833-0190C35825CD Q38817102-2628C3C9-CA0D-4158-92A2-D971BC358E78 Q38838357-AE542879-5972-44D0-9C2D-0F4B8D7E105C Q38866642-ED6B645D-C56E-4E4D-8E26-E839654262BE

P2860

CHK1 inhibition as a strategy for targeting Fanconi Anemia (FA) DNA repair pathway deficient tumors

http://www.wikidata.org/entity/Q37168650

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 16 April 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

CHK1 inhibition as a strategy ...... epair pathway deficient tumors

@en

CHK1 inhibition as a strategy for targeting Fanconi Anemia

@nl

type

label

CHK1 inhibition as a strategy ...... epair pathway deficient tumors

@en

CHK1 inhibition as a strategy for targeting Fanconi Anemia

@nl

prefLabel

CHK1 inhibition as a strategy ...... epair pathway deficient tumors

@en

CHK1 inhibition as a strategy for targeting Fanconi Anemia

@nl

P1433

Q37168650-27924DA2-1064-4144-8A82-1C30F1B97001

P1476

Q37168650-EF230ECC-5F75-420A-8CE6-1FEEC4149C50

P2093

Q37168650-390A8582-F9D2-409F-86E0-1C6DC0919B9B

Q37168650-6D22EB07-1378-4EE4-98E8-7390DA6FCD62

Q37168650-783451CB-0068-4D91-99F6-78D3CB61182B

Q37168650-976B9A18-FAC4-49F1-83AF-B45B11FD3D2A

Q37168650-FF7609EF-BFC7-45B5-812F-B02520BA3387

P2860

Q37168650-100CB467-D7AC-47F7-B5E3-343F47870956

Q37168650-150A24F2-A575-4B3F-94AD-1329AAF5E702

Q37168650-20CBE47E-8C2A-4E44-8BAF-9AC14B8E0844

Q37168650-29EB6837-F246-4B0C-95EC-49E69C4D742F

Q37168650-3748AD8F-2E1D-4A72-B146-FA771C8501D4

Q37168650-38228F53-E802-4051-A421-8D53A015D7D7

Q37168650-412C07BE-A536-4A9D-A3A7-6F875F75F208

Q37168650-41693EF9-D9C9-46E9-AF43-054E4D0B4F06

Q37168650-432233FA-FCC7-43BF-A39E-A8DE52AAA20F

Q37168650-48BE8D31-27A3-4C89-A4F6-CA97F54F7167

P2888

Q37168650-91FCB0DD-667D-4B79-BC9B-E774420E202B

P304

Q37168650-A9467E19-B980-41E0-BD4B-CE6744195D7F

P31

Q37168650-343EE039-DCCA-46F7-957E-C2A3BB2AECD2

P356

Q37168650-C131E5B8-2AB8-4657-A201-723FDE835B9D

P478

Q37168650-ED264888-8EFC-4898-ABAC-6CF3498B3CB3

P577

Q37168650-F3F57C80-AA2A-4093-B2D7-100FFE382F93

P5875

Q37168650-7AF9BC93-2033-4A54-9B03-D9213AF4E372

P6179

Q37168650-FA46575E-2DC5-496D-A7E2-DA4101D151D4

P698

Q37168650-AF88F0F4-9972-4C0E-8856-22D69AC97F09

P932

Q37168650-28B5D7C5-3E17-4B0A-B60F-17C5B4A5D8D4

P356

P1433

Molecular Cancer

P1476

CHK1 inhibition as a strategy ...... epair pathway deficient tumors

@en

P2093

A Thomas Look

http://www.w3.org/2001/XMLSchema#string

Alan D'Andrea

http://www.w3.org/2001/XMLSchema#string

Clark C Chen

http://www.w3.org/2001/XMLSchema#string

Richard D Kennedy

http://www.w3.org/2001/XMLSchema#string

Samuel Sidi

http://www.w3.org/2001/XMLSchema#string

P2860

BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage

MDC1 is a mediator of the mammalian DNA damage checkpoint

The Fanconi anaemia proteins, FAA and FAC, interact to form a nuclear complex

Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint

The selectivity of protein kinase inhibitors: a further update

Chk1-mediated phosphorylation of FANCE is required for the Fanconi anemia/BRCA pathway

Genetic instabilities in human cancers

The fanconi anemia proteins FANCA and FANCG stabilize each other and promote the nuclear accumulation of the Fanconi anemia complex

Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival

Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors

P2888

P304

24

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1476-4598-8-24

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2009-04-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24282399

http://www.w3.org/2001/XMLSchema#string

P6179

1035798193

http://www.w3.org/2001/XMLSchema#string

P698

19371427

http://www.w3.org/2001/XMLSchema#string

P932

2672921

http://www.w3.org/2001/XMLSchema#string